Biotech & Pharmaceuticals

Two new deals to the start the year and positive trial presentations at the J.P. Morgan Health Care conference, have breathed new life into some of last year’s biggest stock losers.

Biotech giant Amgen is lowering the price of its cholesterol medicine Repatha by almost 60 percent, following a similar move from its competitor, after both drugs failed to meet sales expectations.

J&J is still the global leader in the category, but says it needs to make a change to stem a sales decline.

Shkreli, who gained infamy for raising the price of the drug Daraprim by more than 5,000 percent, has been locked up since offering a bounty for hair stolen by Facebook followers from the head of Hillary Clinton.

Since President Trump took office, drugmakers have hiked list prices on hundreds of drugs at rates that outpace inflation, Axios reports.

Celgene agrees to buy biotechnology company Juno Therapeutics for about $9 billion.

Sixty-four percent of patients achieved major depressive disorder remission using SAGE-217 in the 15th day of treatment, Sage says.

Inter partes review is at the center of a case before the Supreme Court, and the decision will have far-reaching effects.

The approvals “mark another significant milestone for our company,” Mylan CEO Heather Bresch says.

Arena Pharmaceuticals’ drug Ralienpag met its Phase 2 program goals.

Lilly says the FDA needed additional data to “characterize safety concerns across treatment arms.”

While the White House and Congress struggled to repeal Obamacare, investors did not shy away from health-care stocks in the first quarter.

Drug maker Mylan said it was recalling select lots of the company’s EpiPen device due to a potential defect.

United Therapeutics said it would be delaying the launch of an implantable pump until 2018.